Scilex Holding Company — Form 8-K Summary
Business context and reporting period
Filed May 3, 2023, under Items 2.02 and 9.01. The company reported preliminary, unaudited ZTlido sales results for April 2023 and year-to-date April 2023. The data had not been completed, reviewed, or audited by the independent auditor.
Key financial metrics
| Metric | April 2023 | April 2022 | Change |
|---|---|---|---|
| ZTlido gross sales | $9.5 million–$11.0 million | $5.1 million | 86%–116% growth |
| ZTlido net sales | $3.2 million–$4.0 million | $1.8 million | 78%–122% growth |
| Metric | Year-to-date April 2023 | Year-to-date April 2022 | Change |
|---|---|---|---|
| ZTlido gross sales | $36.2 million–$39.3 million | $23.5 million | 54%–67% growth |
| ZTlido net sales | $13.0 million–$15.3 million | $8.6 million | 51%–78% growth |
The filing does not provide profit, operating margin, cash flow, debt, liquidity, or balance-sheet metrics.
Material changes versus the prior comparable period
ZTlido gross sales and net sales increased materially compared with April 2022 and the corresponding year-to-date period. The filing provides ranges rather than finalized results.
Guidance, risks, contingencies, and unusual items
- The results are preliminary estimates based on currently available information and may differ materially from actual results, including results outside the stated ranges.
- The company had not completed its review, and the independent auditor had not reviewed or audited the data.
- The Item 2.02 information is furnished rather than filed for liability purposes under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor verification points
- Verify finalized April and first-quarter 2023 results against subsequent financial statements or filings.
- Assess the reconciliation between ZTlido gross sales and net sales, including deductions and channel effects.
- Review profitability, cash usage, debt, liquidity, and any updated operating outlook in subsequent filings.
- Confirm whether the reported sales growth translated into sustainable earnings and cash-flow improvement.